Treatment of hepatitis C virus genotype 4 in the DAA era

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Direct antiviral agents (DAAs) offer effective, interferon-free treatment for hepatitis C virus (HCV).
• HCV genotype 4 (GT4) historically showed lower sustained virological response (SVR) rates compared to other genotypes.
• Limited clinical trial data exists for DAA efficacy specifically in GT4 infections.

Purpose of the Study:

• To review the efficacy of DAA therapy in patients with HCV GT4 infection.
• To analyze recent studies, including real-world 'field-practice' data, on DAA treatment for GT4.
• To assess the effectiveness of specific DAA regimens in this understudied population.

Main Methods:

• Literature review of recent clinical studies and field-practice data.
• Focus on studies evaluating DAA regimens in HCV GT4 infected patients.
• Analysis of reported sustained virological response (SVR) rates and treatment tolerability.

Main Results:

• DAA-based regimens demonstrate high efficacy in HCV GT4 patients.
• Favorable SVR rates are reported across various DAA combinations, including ombitasvir/paritaprevir/ritonavir, sofosbuvir/velpatasvir, and glecaprevir/pibentasvir.
• These positive outcomes are observed even in the less-explored GT4 population and in real-world settings.

Conclusions:

• DAA therapy is effective for treating hepatitis C virus genotype 4 infection.
• Recent studies indicate favorable outcomes and high SVR rates for DAA regimens in GT4 patients.
• DAAs represent a significant advancement for managing HCV GT4, even in challenging clinical scenarios.